Key result
Atherosclerosis risk does not alter Tamsulosin or Tadalafil efficacy for LUTS treatment.
Why the study?
No prior study evaluated the impact of atherosclerosis risk levels on the efficacy of benign prostatic hyperplasia drug therapies.
Does atherosclerosis risk level affect the efficacy of Tamsulosin or Tadalafil in men with LUTS?
RCT (n=82)
randomized
Does atherosclerosis risk level affect the efficacy of Tamsulosin or Tadalafil in men with LUTS?
p-value: p=0.378, 0.975, 0.743
Atherosclerosis risk level, as measured by the Framingham Risk Score, does not appear to influence the efficacy of Tamsulosin or Tadalafil in treating LUTS.
Atherosclerosis risk does not modify tamsulosin or tadalafil efficacy in LUTS; supports uniform dosing irrespective of Framingham score.
Introduction: To date, no study evaluates the effect of atherosclerosis risk level on the efficacy of BPH drug therapies. Therefore, the present study aimed to assess the effect of atherosclerosis risk levels on the effectiveness of Tamsulosin and Tadalafil in LUTS treatment. Methods: The present study was a randomized clinical trial that assessed men with LUTS symptoms (at least six months). The inclusion criteria were being older than 50 years, international prostate symptom score (IPSS) ≥ 13, and maximum urinary flow rate (Qmax) between 4 and 15 ml/s. Framingham Risk Score was used to measure atherosclerosis risk. The patients were classified into four groups, including group 1: Patients with low risk and treated with Tamsulosin (0.4 mg/day), group 2: Patients with low risk and treated with Tadalafil (5 mg/day), group 3: Patients with high risk and treated with Tamsulosin (0.4 mg/day), group 4: Patients with high risk and treated with Tadalafil (5 mg/day). Results: The study included 44 and 38 patients receiving Tamsulosin and Tadalafil, respectively. The means (SD) of the baseline age for the Tamsulosin and Tadalafil groups were equal to 60.6 (6.8) and 58.8 (6.7), respectively (p-value = 0.213). The models revealed no impact of the atherosclerosis risk level on the drugs' effects (p-values = 0.378, 0.975, 0.743 for IPSS, QMAX, and VOID, respectively). Conclusions: The present study's findings could not show the impact of atherosclerosis risk levels on the efficiency of Tamsolusin and Tadalafil in men with LUTS.
No takes yet. Share an insight, caveat, or question.
Tavoosian et al. (2022) conducted an RCT in Lower Urinary Tract Symptoms (LUTS) (n=82). Tamsulosin vs. Tadalafil (5 mg/day) was evaluated on Impact of atherosclerosis risk level on drug efficacy (IPSS, QMAX, and VOID) (p=0.378, 0.975, 0.743). Atherosclerosis risk level had no significant impact on the efficacy of Tamsulosin or Tadalafil for LUTS treatment (p=0.378 for IPSS, p=0.975 for QMAX, p=0.743 for VOID).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: